Belite Bio, Inc (BLTE)

NASDAQ: BLTE · IEX Real-Time Price · USD
30.26
+0.29 (0.95%)
Feb 6, 2023, 1:59 PM EST - Market open
0.95%
Market Cap 752.49M
Revenue (ttm) n/a
Net Income (ttm) -9.67M
Shares Out 24.87M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 785
Open 30.42
Previous Close 29.98
Day's Range 30.10 - 30.42
52-Week Range 8.80 - 44.70
Beta n/a
Analysts Buy
Price Target 58.65 (+93.82%)
Earnings Date n/a

About BLTE

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protei... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 12
Stock Exchange NASDAQ
Ticker Symbol BLTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BLTE stock is "Buy." The 12-month stock price forecast is $58.65, which is an increase of 93.82% from the latest price.

Price Target
$58.65
(93.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, t...

2 months ago - GlobeNewsWire

Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data

“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration”

3 months ago - GlobeNewsWire

Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022

SAN DIEGO, Oct. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, t...

4 months ago - GlobeNewsWire

Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, ...

4 months ago - GlobeNewsWire

Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

SAN DIEGO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, ...

5 months ago - GlobeNewsWire

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.

SAN DIEGO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, t...

6 months ago - GlobeNewsWire

Belite Bio Reports First Half 2022 Operational Highlights and Financial Results

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, today annou...

6 months ago - GlobeNewsWire

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a...

6 months ago - GlobeNewsWire

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatab...

7 months ago - GlobeNewsWire

Biotech Public Offerings at 10-Year Low

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerin...

Other symbols: HLVXPEPGTAKXBI
7 months ago - GuruFocus

Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye ...

9 months ago - GlobeNewsWire

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (the “Company”) (Nasdaq: BLTE),  a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable...

9 months ago - GlobeNewsWire